UP!
|
Type
|
Public |
|---|---|
| Traded as | NASDAQ: OSIR |
| Industry | Pharmaceuticals |
| Headquarters | Columbia, Maryland, United States |
|
Key people
|
Dwayne Montgomery(CEO), Greg Law (CFO), Frank Czworka (COO), Alla Danilkovitch (CSO), Jon Hopper (CMO) |
| Products | Grafix, Cartiform, BIO4, |
| Website | osiris |
Osiris Therapeutics, Inc., based in Columbia, Maryland, is a company researching, developing and marketing regenerative medicine products. One of its products, Stromagen was used to treat breast cancer in clinical trials.
| 2016-03-16 | Reiterated Rating | Brean Capital | Sell | $4.00 |
| 2016-02-04 | Reiterated Rating | Brean Capital | Sell | $8.00 to $4.00 |
| 2016-02-02 | Reiterated Rating | Piper Jaffray | Buy | |
| 2016-02-02 | Reiterated Rating | Piper Jaffray Cos. | Buy | |
| 2015-12-18 | Reiterated Rating | Brean Capital | Sell | $8.00 |
| 2015-11-30 | Reiterated Rating | Piper Jaffray | Buy | |
| 2015-11-19 | Reiterated Rating | Piper Jaffray | Buy | $28.00 |
| 2015-11-17 | Downgrade | Brean Capital | Hold to Sell | $8.00 |
| 2015-11-01 | Reiterated Rating | Brean Capital | Hold | |
| 2015-10-01 | Initiated Coverage | Brean Capital | Buy to Hold | |
| 2015-08-06 | Boost Price Target | Brean Capital | Buy | $19.00 to $25.00 |
| 2015-03-19 | Reiterated Rating | Brean Capital | Buy | $19.00 |
| 2015-03-06 | Set Price Target | Brean Capital | Buy | $19.00 |
| 2015-01-20 | Set Price Target | Brean Capital | Buy | $19.00 |
| 2014-12-29 | Initiated Coverage | Brean Capital | Buy | $19.00 |
| 2014-09-16 | Initiated Coverage | R. F. Lafferty | Buy | $19.00 |
| 2013-10-02 | Upgrade | Piper Jaffray | Neutral to Overweight | $21.00 |
| 2010-01-08 | Initiated | WBB Securities | Sell | $5 |
| 2009-09-08 | Reiterated | Jefferies & Co | Underperform | $7 to $3 |
| 2009-03-31 | Reiterated | Jefferies & Co | Underperform | $11 to $7 |
| 2009-03-05 | Initiated | Wedbush Morgan | Buy | |
| 2008-10-01 | Initiated | JMP Securities | Mkt Outperform | $25 |
| 2008-08-01 | Downgrade | Jefferies & Co | Hold to Underperform | $11 |
| 2008-02-28 | Reiterated | Lazard Capital | Sell | $8 to $5 |
| 2007-02-15 | Reiterated | Jefferies & Co | Hold | $24 to $16 |
| 2007-02-15 | Downgrade | Lazard Capital | Hold to Sell | $14 |
| 2016-03-16 | Reiterated Rating | Brean Capital | Sell | $4.00 |
| 2016-02-04 | Reiterated Rating | Brean Capital | Sell | $8.00 to $4.00 |
| 2016-02-02 | Reiterated Rating | Piper Jaffray | Buy | |
| 2016-02-02 | Reiterated Rating | Piper Jaffray Cos. | Buy | |
| 2015-12-18 | Reiterated Rating | Brean Capital | Sell | $8.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In OSIR 9 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| BlackRock Fund Advisors | 0.63M |
| BlackRock Institutional Trust Company, N.A. | 0.50M |
| BlackRock Investment Management, LLC | 77761 |
| KILLEN GROUP INC | 40000 |
| Shinko Asset Management Co., Ltd. | 35270 |
| Horizon Kinetics LLC | 19000 |
| RUSSELL FRANK CO/ | 11800 |
| BLACKROCK ADVISORS LLC | 8757 |
| NEW ENGLAND SECURITIES CORP /MA/ | 205 |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| FRIEDLI PETER Chairman | 29.74% (10204404) | OSIR / |
| VENTURETEC INC | 11.96% (4103301) | OSIR / |
| Mills C Randal President & CEO | 0.36% (122000) | OSIR / |
| Gutzwiller Felix | 0.25% (84500) | OSIR / |
| BARNHILL GREGORY HURD | 0.24% (82421) | OSIR / PURE / |
| Carmitchel Harry E Chief Operating Officer | 0.20% (70000) | OSIR / |
| Debrabandere Lode Vice President | 0.11% (37500) | OSIR / |
| FENDER EARL R Vice President | 0.11% (37500) | OSIR / |
| MOYES JAY M | 0.08% (26500) | AMDA / OGXI / OSIR / PBYI / |
| DRESNER DAVID A Interim President & CEO | 0.07% (25000) | OSIR / |
| JACOBY PHILIP R JR Vice President of Finance | 0.04% (12500) | OSIR / |
| Danilkovitch Alla Chief Scientific Officer | 0.03% (11950) | OSIR / |
| Klingemann Hans-Georg | 0.02% (6250) | OSIR / |
UM